Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

MRUS

Phase 2

Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®)

1L mCRC (Metastatic colorectal cancer)

H2 2025

1L CRC cohort. 2/27/25- Initial clinical data in H2 2025.

Data readout

VTYX

Phase 2a

VTX3232 (NLRP3 inhibitor)

Early Parkinson's disease

2025

Dosing in Ph1 healthy volunteers. 3/11/24- Reported topline data. 9/6/24- First patient dosed w/ topline data in 2025. 9/23/24 $27M strategic investment from $SNY.

Data readout

GOSS

Phase 3

Seralutinib (GB002) (Inhaled PDGF receptor kinase inhibitor)

PAH (Pulmonary Arterial Hypertension)

Q4 2025

TORREY OLE & PROSERA trials. Interim results from Ph1B & Ph2 TORREY OLE at ATS '24 on May 19th. 8/26/24- Additional Ph2 OLE data at ERS 2024 on September 7-11, 2024. 03/13/25- Topline data in Q4 2025.

Data readout

JANX

Phase 1

JANX008 (EGFR-TRACTr)

Solid tumors

2025

11/7/23- Enrollment ongoing. 2/26/24 Encouraging updated interim data. Continuing in the dose escalation and optimization portion. 5/7/24- Ongoing enrollment w/ data in 2025.

Data readout

CGEM

Phase 1

CLN-978 (CD19xCD3)

Systemic lupus erythematosus (SLE)

Q4 2025

4/16/24- Focusing on SLE indication from recent data. 9/17/24- IND cleared to initiate Ph1. Preclinical data at ACR 2024. 11/14/24- Initial data in Q4 2025.

Initiation

FGEN

Phase 1b/2

FG-3246+ enzalutamide

metastatic castration-resistant prostate cancer (mCRPC)

H2 2025

4/2/24 Conducted at UCSF. 5/24/24 Positive Ph1b interim results at ASCO 2024 on June 2, 2024. Ph2 study in H2 '24. 3/17/25- Topline data from the Ph2 portion in H2 2025.

Data readout

MRUS

Phase 2

Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®)

3L+ mCRC (Metastatic colorectal cancer)

H2 2025

3L+ mCRC trial. 12/16/24- First patient dosed in Ph2. 2/27/25- Initial clinical data in H2 2025.

Data readout

BCYC

Phase 2/3

Zelenectide pevedotin (zele, formerly BT8009) (Nectin-4)

Metastatic bladder (urothelial) cancer

H2 2025

Duravelo-1, 2 trials. 12/13/24- Topline data at SABCS'24 and at a conference call on December 13, 2024. Dose selection and topline data from Duravelo-2 trial in H2 2025. 1/13/25- Updated Ph1 data .

Data readout

BBIO

Phase 3

BBP-418

LGMD2I (Limb-Girdle Muscular Dystrophy Type 2i)

2025

FORTIFY trial: 7/31/23- Dosed the first patient. 9/30/24 Complete enrollment; topline data from interim analysis in 2025.

Data readout

ALNY

Phase 2

Elebsiran (ALN-HBV02 [VIR-2218] +/- VIR-3434)

Chronic hepatitis B & D

2025

SOLSTICE trial. w/ Vir Biotechnology. Report positive preliminary clinical data at EASL '24. 2/13/25- Initiate Ph3 trial and to report results in 2025.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20